ArticleMikrochimica acta2025
MoS₂-DNA tetrahedral bioconjugate for high-performance DNA biosensors: application in viral infection diagnostics.
Article in Mikrochimica acta, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
An electrochemical DNA biosensor is presented for early viral infection detection, integrating molybdenum disulphide (MoS₂), tetrahedral DNA nanostructures (TDNs), and thionine-modified carbon nanodots (CNDsTy). The innovation of this work lies in the first-time integration of these nanomaterials for the preparation of a bioconjugate, whose synergy enables the biosensor's functionality. MoS₂ anchors the TDNs, which carry the capture probe for virus identification via genetic code recognition. CNDsTy allow the electrochemical detection based on their different affinity for single-stranded (ssDNA) and double-stranded DNA (dsDNA), enabling hybridization event identification. The biosensor achieves high sensitivity (detection limit of 5.00 fM) and can distinguish viral loads, validated with the SARS-CoV-2 ORF1ab sequence in human nasopharyngeal samples.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.